Camrelizumab

Generic Name: Camrelizumab

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 1798286-48-2

Unique Ingredient Identifier: 73096E137E

Background: Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).

Indication: ⑴用于至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤患者的治疗。

⑵用于霍奇金淋巴瘤（三线）、肝细胞癌（二线）、非鳞状非小细胞肺癌（一线联合）、食管鳞癌（二线）。

⑶用于既往接受过二线及以上化疗后疾病进展或不可耐受的晚期鼻咽癌患者的治疗。

⑷联合顺铂和吉西他滨用于局部复发或转移性鼻咽癌患者的一线治疗。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery

Not Applicable

Conditions: Hepatocellular Carcinoma

Interventions: Drug: SHR-1210
Drug: apatinib

First Posted Date: 2018-10-29

Last Posted Date: 2018-12-19

Lead Sponsor: Shanghai Zhongshan Hospital

Target Recruit Count: 45

Registration Number: NCT03722875

Locations: 🇨🇳
Zhongshan Hospital, Shanghai, Shanghai, China

Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma

Phase 3

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: Camrelizumab
Drug: Placebos
Drug: Gemcitabine
Drug: Cisplatin

First Posted Date: 2018-10-16

Last Posted Date: 2022-07-01

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 263

Registration Number: NCT03707509

Locations: 🇨🇳
Cancer Center of Sun-Yat Sen University (CCSYSU), Guangzhou, Guangdong, China

Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer

Phase 3

Completed

Conditions: Advanced Esophageal Cancer

Interventions: Drug: Placebo
Drug: SHR-1210
Drug: paclitaxel
Drug: cisplatin

First Posted Date: 2018-10-01

Last Posted Date: 2022-12-07

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 596

Registration Number: NCT03691090

Locations: 🇨🇳
Cancer Center of Sun-Yat Sen University (CCSYSU), Guangzhou, Guangdong, China

Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC

Not Applicable

Conditions: Esophageal Cancer

Interventions: Drug: SHR-1210
Radiation: IMRT or VMAT
Drug: Apatinib

First Posted Date: 2018-09-14

Last Posted Date: 2019-01-09

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 20

Registration Number: NCT03671265

Locations: 🇨🇳
Department of Radiation Oncology, Tianjin Medical University Cancer Hospital, Tianjin, Tianjin, China

A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC

Phase 3

Conditions: Lung Cancer Squamous Cell
Lung Cancer Stage IV
PD-1 Antibody
Chemotherapy Effect

Interventions: Drug: SHR-1210
Drug: The placebo

First Posted Date: 2018-09-12

Last Posted Date: 2021-03-15

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 390

Registration Number: NCT03668496

Locations: 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳
Anhui Chest Hospital, Hefei, Anhui, China
🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China

and more 49 locations

A Study of SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLC

Phase 2

Terminated

Conditions: Lung Neoplasms

Interventions: Drug: SHR-1210
Drug: BP102

First Posted Date: 2018-09-12

Last Posted Date: 2021-03-17

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 5

Registration Number: NCT03666728

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer

Phase 2

Terminated

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: SHR-1210
Drug: BP102
Drug: oxaliplatin
Drug: capecitabine

First Posted Date: 2018-08-24

Last Posted Date: 2019-05-10

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 12

Registration Number: NCT03645876

Locations: 🇨🇳
Cancer Center of Sun-Yat Sen University (CCSYSU), Guangzhou, Guangdong, China

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With FOLFOX4 in Subjects With Advanced HCC Who Have Never Received Prior Systemic Treatment.

Phase 3

Conditions: Advanced Hepatocellular Carcinoma

Interventions: Drug: SHR-1210
Drug: Placebo
Drug: FOLFOX4

First Posted Date: 2018-07-30

Last Posted Date: 2022-02-10

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 396

Registration Number: NCT03605706

Locations: 🇨🇳
81 Hospital Nanjing, Nanjing, Jiangsu, China

SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer

Phase 2

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Drug: SHR-1210
Drug: Apatinib
Drug: Irinotecan Injection
Drug: Paclitaxel liposome
Drug: Nedaplatin

First Posted Date: 2018-07-27

Last Posted Date: 2020-02-11

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 45

Registration Number: NCT03603756

Locations: 🇨🇳
Jing Huang, Beijing, China

A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC

Phase 1

Conditions: NSCLC
HCC
CRC

Interventions: Drug: SHR-1210
Drug: SHR6390

First Posted Date: 2018-07-26

Last Posted Date: 2018-07-26

Lead Sponsor: Harbin Medical University

Target Recruit Count: 41

Registration Number: NCT03601598

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy